NAYA Biosciences, Inc (NAYA) - Net Assets
Based on the latest financial reports, NAYA Biosciences, Inc (NAYA) has net assets worth $12.75 Million USD as of December 2024. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($46.45 Million) and total liabilities ($33.70 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read NAYA Biosciences, Inc (NAYA) total liabilities for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $12.75 Million |
| % of Total Assets | 27.44% |
| Annual Growth Rate | N/A |
| 5-Year Change | 121.96% |
| 10-Year Change | N/A |
| Growth Volatility | 648.92 |
NAYA Biosciences, Inc - Net Assets Trend (2007–2024)
This chart illustrates how NAYA Biosciences, Inc's net assets have evolved over time, based on quarterly financial data. Also explore NAYA total asset value for the complete picture of this company's asset base.
Annual Net Assets for NAYA Biosciences, Inc (2007–2024)
The table below shows the annual net assets of NAYA Biosciences, Inc from 2007 to 2024. For live valuation and market cap data, see how much is NAYA Biosciences, Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $12.75 Million | +1328.13% |
| 2023-12-31 | $892.60K | +191.30% |
| 2022-12-31 | $-977.61K | -113.37% |
| 2021-12-31 | $7.31 Million | +27.29% |
| 2020-12-31 | $5.74 Million | +254.65% |
| 2019-12-31 | $-3.71 Million | -36.32% |
| 2018-12-31 | $-2.72 Million | +45.43% |
| 2017-12-31 | $-4.99 Million | -8.11% |
| 2016-12-31 | $-4.62 Million | -22.91% |
| 2015-12-31 | $-3.76 Million | -51.38% |
| 2010-12-31 | $-2.48 Million | +19.47% |
| 2009-12-31 | $-3.08 Million | -1260.36% |
| 2008-12-31 | $-226.57K | -124.49% |
| 2007-12-31 | $-100.93K | -- |
Equity Component Analysis
This analysis shows how different components contribute to NAYA Biosciences, Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6695052900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $37.00 | 0.00% |
| Other Components | $79.91 Million | 626.89% |
| Total Equity | $12.75 Million | 100.00% |
NAYA Biosciences, Inc Competitors by Market Cap
The table below lists competitors of NAYA Biosciences, Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Onfolio Holdings Inc
NASDAQ:ONFO
|
$2.49 Million |
|
Biosergen AS
ST:BIOSGN
|
$2.49 Million |
|
DGB Asia Bhd
KLSE:0152
|
$2.49 Million |
|
TT Electronics Plc
LSE:TTG
|
$2.49 Million |
|
CDN Maverick Capital Corp.
F:338B
|
$2.48 Million |
|
PolyPlank publ AB
ST:POLY
|
$2.48 Million |
|
Auddia Inc
NASDAQ:AUUD
|
$2.48 Million |
|
WINDFALL GEOTEK
F:L7C2
|
$2.48 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NAYA Biosciences, Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 892,825 to 12,747,473, a change of 11,854,648 (1327.8%).
- Net loss of 9,095,838 reduced equity.
- New share issuances of 1,809,035 increased equity.
- Other factors increased equity by 19,141,451.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-9.10 Million | -71.35% |
| Share Issuances | $1.81 Million | +14.19% |
| Other Changes | $19.14 Million | +150.16% |
| Total Change | $- | 1327.77% |
Book Value vs Market Value Analysis
This analysis compares NAYA Biosciences, Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.05x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | $-46.77 | $2.20 | x |
| 2008-12-31 | $-0.99 | $2.20 | x |
| 2009-12-31 | $-9.01 | $2.20 | x |
| 2010-12-31 | $-6.25 | $2.20 | x |
| 2015-12-31 | $-4.68 | $2.20 | x |
| 2016-12-31 | $-5.31 | $2.20 | x |
| 2017-12-31 | $-5.65 | $2.20 | x |
| 2018-12-31 | $-2.96 | $2.20 | x |
| 2019-12-31 | $-3.82 | $2.20 | x |
| 2020-12-31 | $5.23 | $2.20 | x |
| 2021-12-31 | $3.44 | $2.20 | x |
| 2022-12-31 | $-0.40 | $2.20 | x |
| 2023-12-31 | $0.29 | $2.20 | x |
| 2024-12-31 | $41.18 | $2.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NAYA Biosciences, Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -71.35%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -139.25%
- • Asset Turnover: 0.14x
- • Equity Multiplier: 3.64x
- Recent ROE (-71.35%) is above the historical average (-86.26%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 0.00% | 0.00% | 0.00x | 0.00x | $-204.00K |
| 2008 | 0.00% | -4930.66% | 0.05x | 0.00x | $-1.85 Million |
| 2009 | 0.00% | -7375.39% | 0.14x | 0.00x | $-4.35 Million |
| 2010 | 0.00% | -226.81% | 0.37x | 0.00x | $94.76K |
| 2015 | 0.00% | -42426.61% | 0.02x | 0.00x | $-4.58 Million |
| 2016 | 0.00% | -4173.30% | 0.18x | 0.00x | $-1.66 Million |
| 2017 | 0.00% | -248.87% | 1.06x | 0.00x | $-202.95K |
| 2018 | 0.00% | -622.22% | 0.64x | 0.00x | $-2.80 Million |
| 2019 | 0.00% | -146.43% | 0.82x | 0.00x | $-1.80 Million |
| 2020 | -145.34% | -804.73% | 0.09x | 1.91x | $-8.92 Million |
| 2021 | -91.03% | -159.97% | 0.40x | 1.43x | $-7.39 Million |
| 2022 | 0.00% | -1324.81% | 0.22x | 0.00x | $-10.79 Million |
| 2023 | -899.91% | -266.00% | 0.16x | 20.73x | $-8.12 Million |
| 2024 | -71.35% | -139.25% | 0.14x | 3.64x | $-10.37 Million |
Industry Comparison
This section compares NAYA Biosciences, Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,432,799,891
- Average return on equity (ROE) among peers: -74.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NAYA Biosciences, Inc (NAYA) | $12.75 Million | 0.00% | 2.64x | $2.48 Million |
| Abbott Laboratories (ABT) | $24.16 Billion | 9.46% | 0.81x | $155.56 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-13.54K | 0.00% | 0.00x | $21.60 Million |
| Aethlon Medical Inc (AEMD) | $9.29 Million | -84.45% | 0.15x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $105.73 Million | -116.68% | 0.61x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $1.39 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $2.15 Million | -112.84% | 0.45x | $16.04 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $8.60 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $644.00K | -309.01% | 0.34x | $4.22 Million |
| Artivion Inc (AORT) | $89.39 Million | 8.74% | 0.25x | $1.73 Billion |
| Apyx Medical Inc (APYX) | $21.15 Million | 2.82% | 0.30x | $125.55 Million |
About NAYA Biosciences, Inc
INVO Fertility, Inc., a life science portfolio company, develops clinical stage assets to treat patients with fertility, oncology, and autoimmune diseases. The company operates in two divisions, NAYA Women's Health and NAYA Therapeutics. Its lead product includes NY-303, a GPC3-targeted FLEX-NK bispecific antibody that is in Phase I/II clinical trials for hepatocellular carcinoma, as well as soli… Read more